Get the Stockscreener App
0.225
4.88%
-0.0128
Jupiter Neurosciences Inc stock is traded at $0.225, with a volume of 4.06M.
It is down -4.88% in the last 24 hours and down -42.01% over the past month.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
See More
Previous Close:
$0.2378
Open:
$0.2366
24h Volume:
4.06M
Relative Volume:
0.84
Market Cap:
$9.74M
Revenue:
-
Net Income/Loss:
$-8.64M
P/E Ratio:
-0.8786
EPS:
-0.2561
Net Cash Flow:
$-5.41M
1W Performance:
-29.31%
1M Performance:
-42.01%
6M Performance:
-81.31%
1Y Performance:
-63.52%
1-Day Range:
$0.2209
$0.24
1-Week Range:
$0.1721
$0.5298
52-Week Range:
$0.1721
$3.33
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Name
Jupiter Neurosciences Inc
Sector
Industry
Phone
(561) 406-6154
Address
1001 NORTH US HWY 1, JUPITER
Compare JUNS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
0.2243 | 10.33M | 0 | -8.64M | -5.41M | -0.2561 |
VRTX
Vertex Pharmaceuticals Inc
|
437.62 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.93 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.39 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.04 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.69 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jupiter Neurosciences Inc Stock (JUNS) Latest News
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering - newswire.com
JUNS Q4 2025 Earnings: Narrower Loss Surprises, Yet Stock Falls on Pre‑Revenue PathPopular Market Picks - Newser
Jupiter Neurosciences (JUNS) Q4 2025 Earnings: EPS Beat Masks Zero-Revenue Reality; Shares Slide 12%Free Signal Network - Newser
What is Driving Jupiter Neurosciences' Recent Stock Volatility - Kavout
A Tiny Psychedelic Stock Just Exploded Over 50% – Retail Traders Think $1 Is Next - Stocktwits
JUNS stock sees best single-day gains in almost a year on $100M MDMA drug licensing deal – retail expects shares to hit $1 - MSN
Jupiter Neurosciences, Inc. Secures $2 Million in Direct Offering to Support Parkinson’s Program and Strengthen Balance Sheet - Quiver Quantitative
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering - marketscreener.com
$2M cash injection backs Jupiter Parkinson’s trial plans - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
What's going on in today's after hours session - ChartMill
Jupiter Neurosciences (JUNS) priced 7.14M-share direct offering at $0.28 - Stock Titan
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Jupiter Neurosciences Announces Registered Direct Equity Offering - TipRanks
Jupiter Neurosciences (NASDAQ: JUNS) files May 21, 2026 prospectus supplement - Stock Titan
Jupiter Neurosciences Prices $2.0 Million Registered Direct Offering at $0.28 Per Share - TradingView
Jupiter Neurosciences (JUNS) raises $2.0M in registered direct stock sale - Stock Titan
Jupiter Neurosciences (JUNS) raises $2.0M via 7.14M-share placement - Stock Titan
Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale - TechStock²
Jupiter Neurosciences Secures $100M Term Sheet for U.S. Rights to PharmAla’s MDMA Therapy ALA-002 - The National Law Review
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering - marketscreener.com
Biopharmaceutical Jupiter Neurosciences plans $2M stock sale - Stock Titan
Jupiter stock soars after $100 million ALA-002 licensing deal - MSN
Most active stocks in Wednesday's session - ChartMill
Jupiter Neurosciences Licenses PharmAla Biotech Lead Psychedelic Drug - HarianBasis.co
PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF) - Yahoo Finance
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to PharmAla’s Next-Generation MDMA Therapeutic ALA-002 After Landmark Executive Order 1 - Minichart
Jupiter Stock Soars After $100 Million ALA-002 Licensing DealJupiter Neurosciences (NASDAQ:JUNS) - Benzinga
Jupiter Neurosciences (NASDAQ: JUNS) inks term sheet for ALA-002 U.S. rights - Stock Titan
Traders are paying attention to the gapping stocks in Wednesday's session. - ChartMill
Jupiter Neurosciences Pursues MDMA Asset Licensing Deal - TipRanks
Jupiter Neurosciences signs term sheet to acquire U.S. rights to ALA-002 with $3.33M upfront - TradingView
Jupiter Neurosciences (NASDAQ: JUNS) pursues exclusive U.S. rights to ALA-002 - Stock Titan
Jupiter Neurosciences stock surges on MDMA therapy licensing deal By Investing.com - Investing.com South Africa
Jupiter Neurosciences stock surges on MDMA therapy licensing deal - Investing.com
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million - The Manila Times
Stay updated with the stocks that are on the move in today's pre-market session. - ChartMill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Jupiter Neurosciences, Inc. Enters Agreement to Acquire U.S. Rights for ALA-002, Advancing Position in MDMA-Based Therapeutics Amid Regulatory Changes - Quiver Quantitative
After Trump psychedelics order, Jupiter signs $100M MDMA term sheet - Stock Titan
Jupiter Neurosciences (JUNS) Q4 2025 Earnings Beat: Revenue $N/A, EPS $-0.07Pricing Power - Newser
JUNS Stock Price, Quote & Chart | JUPITER NEUROSCIENCES INC (NASDAQ:JUNS) - ChartMill
Jupiter Neurosciences (NASDAQ: JUNS) posts Q1 loss, cites going-concern; SEPA noted - Stock Titan
Jupiter Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Jupiter Neurosciences (JUNS) Q1 2026 loss, Nasdaq warnings and cash burn detailed - Stock Titan
Number of shareholders of Jupiter Neurosciences, Inc. – NASDAQ:JUNS - TradingView
What Jupiter Neurosciences (JUNS) is doing that smart investors recognize (Smart Money Flows) 2026-05-11Breadth Thrust - Newser
Jupiter Neurosciences: Resveratrol for neuroinflammation & CNS diseases - MSN
Jupiter Neurosciences (NASDAQ: JUNS) files 10‑K; Phase IIa IND for Parkinson’s cleared - Stock Titan
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit - TradingView
Jupiter Neurosciences Inc Stock (JUNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Jupiter Neurosciences Inc Stock (JUNS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Silva Alison D. | Pres + Chief Business Officer |
Jul 01 '25 |
Buy |
1.03 |
750 |
772 |
112,777 |
| ROSEN CHRISTER | CEO and Chairman |
Jul 01 '25 |
Buy |
1.02 |
3,600 |
3,667 |
11,078,892 |
| Silva Alison D. | Pres + Chief Business Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
110,227 |
0 |
110,227 |
| Silva Alison D. | Pres + Chief Business Officer |
Jun 30 '25 |
Buy |
1.03 |
950 |
978 |
112,027 |
| Silva Alison D. | Pres + Chief Business Officer |
Jun 27 '25 |
Buy |
1.03 |
850 |
877 |
111,077 |
| ROSEN CHRISTER | CEO and Chairman |
Jun 02 '25 |
Option Exercise |
0.00 |
973,466 |
0 |
11,067,476 |
| ROSEN CHRISTER | CEO and Chairman |
Jun 30 '25 |
Buy |
1.02 |
7,650 |
7,810 |
11,075,292 |
| ROSEN CHRISTER | CEO and Chairman |
Jun 27 '25 |
Buy |
1.06 |
166 |
176 |
11,067,642 |
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):